4Heffner JE, Nietert PJ, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions [ J ]. Chest, 2000, 117(1) :79 -86.
6Tamsma JT, Keizer H J, Meinders AE. Pathogenesis of malignant ascites : Starling' s law of capillary hemodynamics revisited [ J ]. Ann Oncol,2001,12(10) : 1353 - 1357.
7Kim YM, Hwang S, Kim YM, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1 [J]. J Biol Chem ,2002,277 ( 31 ) :27872 - 27879.
8Hajitou A, Gfignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells [ J ]. FASEB J ,2002,16(13) :1802 - 1804.
9Urbich C, Reissner A, Chavakis E, et al. Dephosphorylation of endothelial nitric oxide synthase contributes to the anti-angiogenic effects of endostatin [ J ]. FASEB J, 2002,16 ( 7 ) : 706 - 708.
10Lee SJ, Jang JW, Kim YM, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2 [ J ]. FEBS Lett ,2002,519 (1 -3) :147 -152.
